Sanofi CEO Paul Hudson

How bad­ly does Sanofi chief Paul Hud­son want Prin­cip­ia? Enough to ink a $3.7B buy­out deal, dou­bling down on MS

Sanofi CEO Paul Hud­son has a home for a chunk of that Re­gen­eron mon­ey sit­ting in the bank.

The phar­ma ex­ec is shelling out $100 a share to take out Prin­cip­ia $PRNB — helmed by Mar­tin Babler — and the MS drug that Hud­son has been talk­ing up for months as a break­through in the field. That’s a $3.7 bil­lion deal.

Prin­cip­ia has a whole port­fo­lio of BTK in­hibitors in the pipeline, but it’s ‘168 that is the jew­el in the crown for Hud­son, a part­nered drug which he is now dou­bling down on to help push the “on­go­ing R&D trans­for­ma­tion” at Sanofi. Be­yond MS the brain-pen­e­trat­ing drug has po­ten­tial in oth­er CNS dis­eases, of­fer­ing a po­ten­tial pipeline in a prod­uct.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.